Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.

ABSTRACT:

Introduction

Nectin-4 is a tumor-associated antigen overexpressed in urothelial carcinoma and several other malignancies. It has emerged as a compelling target for novel tumor-directed therapies, particularly as a component of antibody-drug conjugates (ADCs), a growing class of anti-cancer therapeutic agents. Development of nectin-4-directed therapies has been led by enfortumab vedotin (EV), an ADC comprised of a fully human monoclonal antibody specific for nectin-4 conjugated via a cleavable linker to the microtubule inhibitor MMAE. EV was approved in 2019 as a first-in-class agent for the treatment of urothelial carcinoma.

Areas covered

This article discusses general principles relevant to ADC design and our current understanding of nectin-4 in normal physiology and malign

SUBMITTER: Wong JL 

PROVIDER: S-EPMC8224177 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature